Sarep­ta dos­es first pa­tient with Duchenne gene ther­a­py fol­low­ing ac­cel­er­at­ed ap­proval

Just over a month af­ter re­ceiv­ing ac­cel­er­at­ed ap­proval from the FDA, Sarep­ta Ther­a­peu­tics has giv­en the first com­mer­cial dose of its Duchenne mus­cu­lar dy­s­tro­phy gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.